Efficacy results, safety data, and survival data from the phase 2 study were presented at the ASCO 2025 Annual Meeting.
KRAS+ Non-Small Cell Lung Cancer
Advertisement
Kathryn C. Arbour, MD, of the Memorial Sloan Kettering Cancer Center, presented results from the study at AACR 2025.
Margarita Majem, MD, PhD, presented the results as a late-breaking abstract during the European Lung Cancer Congress 2025.
Marina Garassino, MD, presented results from the phase 2 portion of the trial at the European Lung Cancer Congress.
Researchers evaluated if demographics, clinical characteristics, and outcomes varied between those with KRAS G12C and G12D.
A team integrating clinical, dual-energy spectral computed tomography, and radiomics features into a predictive model.
Glecirasib, also known as JAB-21822, is an oral, covalent KRAS G12C inhibitor.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
Researchers say the results support the evaluation of the treatment in the phase 3 CodeBreaK 202 trial.
MK-1084 as monotherapy and in combination with pembrolizumab is effective in patients with NSCLC.
Results of a study that evaluated the impact of comprehensive versus limited NGS for advanced NSCLC.
Researchers examined the demographic and clinical outcomes in patients with KRAS-mutated tumors, using patients with NSCLC.
Patients of Hispanic/Latino ethnicity have a greater prevalence of certain lung cancer driver mutations.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.